PTO/SB/88A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent And U.S. Patent Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent Office:

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

ond to a collection of information unless it dis	DIAYS & VALLO ONTO COM
Application Number Filing Date First Named Inventor	10/720,323 November 24, 2003 Jill Giles-Komar
Group Art Unit Examiner Name Attorney Docket Number	CEN 249 CIPNP

			Name of Patentee or Applicant of Cited Document	of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear
No.1	Number	(if known)		10-07-1997	
A	5,674,483			11-16-1999	
12	5,985,278			04-09-2002	
43	6,369,204	B1		03-19-2002	
	6,359,126			01-09-2001	
AS	6,171,588	_		08-02-2001	
	2001/0011125	A1		05-19-1998	
1	5,753,230		Brooks et al		
-					
	A1 A2 A3 A4 A5 A6	Cite No.¹ Number  \$1, 5,674,483  \$2, 5,985,278  \$3, 6,369,204  \$4, 6,359,126  \$4, 6,371,588  \$4, 2001/0011125	No.¹ Number (if known)  #1 5,674,483  #2 5,985,278  #3 6,369,204  #4 6,359,126  #5 6,171,588  #1 2001/0011125  #1 At 2001/0011125	Cite No.¹ Number (if known)  Name of Patenties of Application of Cited Document  Yuan-Po Tu et al  Francesc Mitjans et al  Kyung Jin Kim et al  Kyung Jin Kim et al  Kyung Jin Kim et al  Christopher P. Carron et al  William D. Huse  Brooks et al	Cite         Kind Code*         Name of Patenties of Approximation of Cited Document         of Cited Document         of Cited Document           M1         5,674,483         Yuan-Po Tu et al         10-07-1997           M2         5,985,278         Francesc Mitjans et al         11-16-1999           M3         6,369,204         B1         Kyung Jin Kim et al         03-19-2002           M4         6,359,126         B1         Kyung Jin Kim et al         03-19-2002           M5         6,171,588         B1         Christopher P. Carron et al         08-02-2001           M6         2001/0011125         A1         William D. Huse         05-19-1998

			FO	REIGN PATENT DOCUMENTS	T Date of Publication	Pages, Columns, Lines,	
Ļ	Foreign I	Patent Documer		Name of Patentee or	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear	Tº
	Office <sup>3</sup>	Number <sup>4</sup> Kir	ndCode <sup>5</sup>		08-02-2000		↓_
BI	wo	0031248	Α		08-03-2000		<del> </del>
137	wo	0044404	A		09-28-1995		_
122	wo	95/25543	A1				
18 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	wo	97/06791	A1	Scripps Research Institute			Τ_
137	wo	97/36859	A1	G. D. Searle & Co.		+	T
1 ~ /	1	93/20229	A1	Genentech, Inc.			$\top$
155	<del>'</del>	719859	A1	Merck Patent GMBH	07-03-1996		
	Cite No.1 B1 BZ B3 B4	Cite No.1 Office3 B I WO B Z WO B Z WO B J WO	Cite No.¹ Office³ Number⁴ Kin  B   WO 0031248  B   WO 0044404  B   WO 95/25543  S   WO 97/06791  B   WO 93/20229	Cite No.¹ Office³ Number⁴ KindCode⁵  S I WO 0031248 A  S 7 WO 0044404 A  S 3 WO 95/25543 A1  S 4 WO 97/06791 A1  S 5 WO 97/36859 A1  S 6 WO 93/20229 A1	Cite No.¹ Office³ Number⁴ KIndCode⁵  Applicant of Cited Document  B   WO 0031248   A   Smithkline Beecham Corp.  Children¹a Hospital  S   WO 95/25543   A1   Scripps Research Institute  S   WO 97/06791   A1   Scripps Research Institute  S   WO 97/36859   A1   G. D. Searle & Co.  B   WO 93/20229   A1   Genentech, Inc.	Foreign Patent Document   Name of Patentee or Applicant of Cited Document mm-dd-yyyy	Name of Patentee or Applicant of Cited Document mm-dd-yyyy   Dassages or relevant figures appear

MUBILITY	Date 1/27/06
Examiner Maha Haddad  Signature Haddad  EXAMINER: Initial if reference considered, whether or not citation is in conformance with Mahamatan to applicant.	Considered PEP 609. Draw line through citation if not in conformance and not
Signature 17 (0/7/7 whether or not citation is in conformance with the extremely state of the conformance with the	and the second s
*EXAMINER: Initial if reference considered, whether or applicant, considered, Include copy of this form with next communication to applicant, considered, Include copy of this form with next communication to applicant.	ter Office that issued the document, by the two-letter

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, a Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, a Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Alexandria, VA 22313-1450.
PTO/SB/084 (08-00)
Approved for use through 10/31/2002. 0MB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	and action of information unless it disp	ays a valio othe to
and all those on persons are required to respo	nd to a conscion of the	10/720,323
Under the Paperwork Reduction Act of 1995, no persons are required to respo	Application Number	November 24, 2003
Substitute for form 1449APTO	Filing Date	Jill Giles-Komar
THE PICCI OCURE	FIRST Mairied Invente.	Jiii Giles Harris
INFORMATION DISCLOSSITE	Group Art Unit	
	Examiner Name	CEN 249 CIPNP
(use as many sheets as necessary)	Attorney Docket Number	OL.VIII
Chaot 2 of 3		

Sheet 2 of 3

		U.S. Patent Document			Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear
Examiner nitiats No.1 Number (if known)		of Cited Document	mm-dd-yyyy	Q lucraming.			
		·					
	-						
	+-	<del> </del>					
	+-						
	上						·
	$\prod_{i=1}^{n}$			<del> </del>			

Pages, Columns, Lines, Date of Publication where relevant of Cited Document Foreign Patent Document passages or relevant TO Name of Patentee or mm-dd-yyyy figures appear Applicant of Cited Document Cite Examiner KindCode5 Office<sup>3</sup> Number<sup>4</sup> Initials 06/09/1994 Merck & Co., Inc. 94/12181 A1 wo MH

Examiner Signature Signature State Initial if reference considered, whether or no "EXAMINER: Initial if reference considered, whether or mo "EXAMINER: Initial if reference of this form with next communications and the second of this form with next communications."	Date Considered  Considered  Considered  Considered	1/27/66 w line through citation if not in conformance and no
*EXAMINER: Initial if reference considered, whether of no considered. Include copy of this form with next communications and the considered of the communications are considered.	ation to applicant.	issued the document, by the two-letter

1 Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.



Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number.

work Reduction Act of 1995, no persons are required to respo

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 3 of 3

ond to a collection of information unless it disp	lays a valid OMB control number.
Application Number	
Application No.	November 24, 2003
Filing Date First Named Inventor	Jill Giles-Komar
First Named Inventor	1644
Group Art Unit	
Examiner Name	CEN 249 CIPNP
Attorney Docket Number	

		PAYC	
		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item  Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item  Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item  Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item  Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item  Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item  Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item  Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the article (when appropri	. 1
-		Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the article (when ap	T2
		located name of the author (in CAPTIOE Estatements), date, page(s), volume saud manufacture and page(s), volume saud manuf	1
	I	(book, magazine, journal, serial, symposium, catalog, etc.), dato published publisher, city and/or country where published publisher city and country where published publisher city and country where published publisher city and/or country where published publisher city and ci	
xaminer's	Cite		
nitials*	No.1	A CRIPATIAN (ReoPro, Chimeric 7E3 Fab) Deficition and 1011 USA	
		TAM et al., "Apotential," vol. 98, No. 11, 09-15-1998, pages 10-95-1031 iib/Illa and o.B. Integrins," vol. 98, No. 11, 09-15-1998, pages 10-95-1031 iib/Illa and o.B. Integrins," vol. 98, No. 11, 09-15-1998, pages 10-95-1031 iib/Illa and o.B. Integrins," vol. 98, No. 11, 09-15-1998, pages 10-95-1031 iib/Illa and o.B. Integrins," vol. 98, No. 11, 09-15-1998, pages 10-95-1031 iib/Illa and o.B. Integrins," vol. 98, No. 11, 09-15-1998, pages 10-95-1031 iib/Illa and o.B. Integrins," vol. 98, No. 11, 09-15-1998, pages 10-95-1031 iib/Illa and o.B. Integrins," vol. 98, No. 11, 09-15-1998, pages 10-95-1031 iib/Illa and o.B. Integrins," vol. 98, No. 11, 09-15-1998, pages 10-95-1031 iib/Illa and o.B. Integrins," vol. 98, No. 11, 09-15-1998, pages 10-95-1031 iib/Illa and o.B. Integrins," vol. 98, No. 11, 09-15-1998, pages 10-95-1031 iib/Illa and o.B. Integrins," vol. 98, No. 11, 09-15-1998, pages 10-95-1031 iib/Illa and o.B. Integrins," vol. 98, No. 11, 09-15-1998, pages 10-95-1031 iib/Illa and o.B. Integrins," vol. 98, No. 11, 09-15-1998, pages 10-95-1031 iib/Illa and o.B. Integrins," vol. 98, No. 11, 09-15-1998, pages 10-95-1031 iib/Illa and o.B. Integrins," vol. 98, No. 11, 09-15-1998, pages 10-95-1031 iib/Illa and o.B. Integrins," vol. 98, No. 11, 09-15-1998, pages 10-95-1031 iib/Illa and o.B. Integrins, vol. 41, Illa and	A
m#		invilla and the same application for a carolovascular training of the American Association for Cancer Research,	
		TRIKHA et al., A policy of the control of the cell adhesion protein receptor recognizing vitronectin reveal a March 2000, page 577, USA.  SUZUKI et al. "CDNA and amino acid sequences of the cell adhesion protein receptor," Cell Biology, November 1986, pages 8814-	
mt		and alpha/beats integrated and amino acid sequences of the cell adhesion protein receptor recognizing vironecum reveal of March 2000, page 577, USA.  SUZUKI et al. *cDNA and amino acid sequences of the cell adhesion protein receptors, *Cell Biology, November 1986, pages 8614-transmembrane domain and homologies with other adhesion protein receptors, *Cell Biology, November 1986, pages 8614-transmembrane domain and homologies with other adhesion protein receptors, *Cell Biology, November 1986, pages 8614-transmembrane domain and homologies with other adhesion protein receptors, *Cell Biology, November 1986, pages 8614-transmembrane domain and homologies with other adhesion protein receptor, *Cell Biology, November 1986, pages 8614-transmembrane domain and homologies with other adhesion protein receptors, *Cell Biology, November 1986, pages 8614-transmembrane domain and homologies with other adhesion protein receptors, *Cell Biology, November 1986, pages 8614-transmembrane domain and homologies with other adhesion protein receptors, *Cell Biology, November 1986, pages 8614-transmembrane domain and homologies with other adhesion protein receptors, *Cell Biology, November 1986, pages 8614-transmembrane domain and homologies with other adhesion protein receptors, *Cell Biology, November 1986, pages 8614-transmembrane domain and homologies with other adhesion protein receptors, *Cell Biology, November 1986, pages 8614-transmembrane domain and homologies with other adhesion protein receptors, *Cell Biology, November 1986, pages 8614-transmembrane domain and homologies with other adhesion protein receptors, *Cell Biology, November 1986, pages 8614-transmembrane domain and homologies with other adhesion protein receptors, *Cell Biology, November 1986, pages 8614-transmembrane domain and *Cell Biology, November 1986, pages 8614	1
		March 2000, beg . CDNA and amino acid sequences of the Cell action receptors, "Cell Biology, November 1966, pages	
. 11	Γ	SUZUKI et al., COIVA and homologies with other adhesion protein receptory transmembrane domain and homologies with other adhesion protein receptory and bitronectin of a colon carcinoma cell line and 8618, vol. 83, Proc. National Academy Science, USA.  LEHMANN ET AL. "A monodonal antibody inhibits adhesion to fibronectin and bitronectin of a colon carcinoma cell line and 8618, vol. 83, Proc. National Academy Science, USA.  LEHMANN ET AL. "A monodonal antibody inhibits adhesion to fibronectin and bitronectin of a colon carcinoma cell line and 8618, vol. 83, Proc. National Academy Science, USA.  LEHMANN ET AL. "A monodonal antibody inhibits adhesion to fibronectin and bitronectin of a colon carcinoma cell line and 8618, vol. 83, Proc. National Academy Science, USA.	
MH	l	transmentative of the state of	
		8618, Vol. 35, 1 4 A monoclonal antibody inhibits addressor 1004, pages 2102-2107, Vol. 50, USA	
11	Ι	8618, vol. 83, Proc. National Academy State of the process of the	
mH		recognizes the integrins a, \$\(\beta\), a, \$\(\beta\), a, \$\(\beta\), a, \$\(\beta\), and the integrins a, \$\(\beta\), a, \$\(\beta\), and the integrins a state of the integrins and the integrits and the integrins and the integrins and the integrits and the integrins and the integrits and the integrity and the integrit	
MH	T	GUNTHER AND ANDREA KRAFT, "Angiogenesis as a target for turner of slope wintening during angiogenesis: insignis title poor	
7"1"	l		
100 14			
mtt	1	MECHANIST SOURCE ANDER PETER C. BROOKS, ROBERT COSENIC PATHWAYS BY DISTINCT ALPHA-VIIVES	•
		MARTIN PRIEDLY CHERESH. DEFINITION OF TWO ANGIOGENIC PARTIES	
m#	1	AND DAVID A. 1995 1500-2 vol. 270.	
17.0		Science, Dec 1 OR CONDIF E CARMACK, DENNIS HUSZAR, CUISAN I O'DONNELL, ROBERT M. KAY, O'DONNELL,	
		LISA D. TAYLOR, CONDIE E. CARMACK, DENNIS HUSZAH, NAT.  LISA D. TAYLOR, CONDIE E. CARM	
- 11	1	SEQUAH, STEPHEL STONBERG, "Human immunoglobust tall beginning 1994; 579-91, vol. 6 no. 4, Oxford Ottavelous	
mH	1	WOODHOOSE, All and lack endogenous IgM, International transfer of the state of the	
	1	dass switching withing the same of the sam	
	1	Press. DIANES D. TAYLOR, FIONA A. HARDING, WATHRYN WYMORE, JAMES G. MCCADE, MANNE M.	ì
		Press.  NILS LONBERG, USA D. TAYLOR, FIONA A. HAHDING, MYMORE, JAMES G. MCJABE,  NILS LONBERG, USA D. TAYLOR, FIONA A. HAHDING, MYMORE, JAMES G. MCJABE,  NILS LONBERG, USA D. TAYLOR, FIONA A. MSHAYEKH, KATHRYN WYMORE, JAMES G. MCJABE,  SCHRAMM, CHIUNG-CHI KUO, ROSHANAK MASHAYEKH, KATHRYN WYMORE, JAMES G. MCJABE, DIANNE M.  SCHRAMM, CHIUNG-CHI KUO, ROSHANAK MASHAYEKH, KATHRYN WYMORE, JAMES G. MCJABE, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G. LAPACHET, TASH BENGOECHEA, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G. LAPACHET, TASH BENGOECHEA, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G. LAPACHET, TASH BENGOECHEA, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G. LAPACHET, TASH BENGOECHEA, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G. LAPACHET, TASH BENGOECHEA, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G. LAPACHET, TASH BENGOECHEA, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G. LAPACHET, TASH BENGOECHEA, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G. LAPACHET, TASH BENGOECHEA, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G. LAPACHET, TASH BENGOECHEA, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G. LAPACHET, TASH BENGOECHEA, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G. LAPACHET, TASH BENGOECHEA, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G. LAPACHET, TASH BENGOECHEA, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G. LAPACHET, TASH BENGOECHEA, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G. LAPACHET, TASH BENGOECHEA, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G. LAPACHET, TASH BENGOECHEA, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G. LAPACHET, TASH BENGOECHEA, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G. LAPACHET, TASH BENGOECHEA, DIANNE M.  MUNOZ-O'REGAN, SUSAN L. O'DONNELL, EUZABETH S. G.	1
للمد	1	SCHRAMM, CHICAN I COONNELL EUZABETH STAND ANTIOEN-SPECIAL NUMBER ANT	1
mt	- }	MONOTOR D. CONDIE E. CARMACK, ROBERT M. NAT 128 1994 856-9, vol. 368.	1
H	- 1		1
1			1
MH		MICHAEL NEGENAULD SUSAN L. O'DONNELL, TASH BENGGETING STEPHEN R. SCHRAMM, AND NILS LONBERS,	l
		DIANNE M. FISHVILLY, TONES, ROBERT M. KAY, KAY M. HIGGING strain of minilocus transgenic mice, Nature	1
١ ١٠	ļ	MICHAEL NEUBERGER, "Ganerating high-avidity human Mass Introduced the Michael Neuberger, "Ganerating high-avidity human Mass Introduced the Michael Neuberger, "Ganerating high-avidity human Londerg, Nature Thigh-avidity human IgG-kappa monoclonal antibodies from a novel strain of minitiocus transgenic mice," Nature Thigh-avidity human IgG-kappa monoclonal antibodies from a novel strain of minitiocus transgenic mice, "Nature Thigh-avidity human IgG-kappa monoclonal antibodies from a novel strain of minitiocus transgenic mice," Nature Thigh-avidity human IgG-kappa monoclonal antibodies from a novel strain of minitiocus transgenic mice, "Nature Thigh-avidity human IgG-kappa monoclonal antibodies from a novel strain of minitiocus transgenic mice," Nature Thigh-avidity human IgG-kappa monoclonal antibodies from a novel strain of minitiocus transgenic mice, "Nature Thigh-avidity human IgG-kappa monoclonal antibodies from a novel strain of minitiocus transgenic mice," Nature Thigh-avidity human IgG-kappa monoclonal antibodies from a novel strain of minitiocus transgenic mice, "Nature Thigh-avidity human IgG-kappa monoclonal antibodies from a novel strain of minitiocus transgenic mice," Nature Thigh-avidity human IgG-kappa monoclonal antibodies from a novel strain of minitiocus transgenic mice, "Nature Thigh-avidity human IgG-kappa monoclonal antibodies from a novel strain of minitiocus transgenic mice," Nature Thigh-avidity human IgG-kappa monoclonal antibodies from a novel strain of minitiocus transgenic mice, "Nature Thigh-avidity human IgG-kappa monoclonal antibodies from a novel strain of minitiocus transgenic mice," Nature Thigh-avidity human IgG-kappa monoclonal antibodies from a novel strain of minitiocus transgenic mice, "Nature Thigh-avidity human IgG-kappa monoclonal antibodies from a novel strain of minitiocus transgenic mice," Nature Thigh-avidity human IgG-kappa monoclonal antibodies from a novel strain of minitiocus transgenic mice, "Nature Thigh-avidity human IgG-kappa monoclonal antibodies from a novel	+
MH	1	High-avidity human IgG-kappa monoclonal antibodies from a libror and libror a	1
H	1	Biotechnology, July NEE ROBERT A. ORLANDO AND DAVID A. CHELING on the Cell Surface," J. Cell Biology, May 1991, 815	1
10 11		ELIZABETH A WATER-ING TO Vitronectin but Differentially Distribute of the Samuel Control	+
mn	·	ELIZABETH A. Workment to Vitronectin but Differentially Distribute to Cell Attachment to Vitronectin but Differentially Distribute to Cell Attachment to Vitronectin and Elizabeth S. S. MCCARTNEY, FRANCESC MITJANS, SIMON L. 29, vol. 113, no. 4.  JOHN F. MARSHALL, DEBORAH C. RUTHERFORD, ALISON C.E. MCCARTNEY, FRANCESC MITJANS, SIMON L. 29, vol. 113, no. 4.  JOHN F. MARSHALL, DEBORAH C. RUTHERFORD, ALISON C.E. MCCARTNEY, FRANCESC MITJANS, SIMON L. 29, vol. 113, no. 4.	
II .	- 1	29, vol. 113, 103, 41. DEBORAH C. RUTHERFORD, ALISON C.E. Mooretin and fibrinogen, and acts with alpha 5 beta 1 to	1
1		JOHN F. MANSHALL, AND AN B. HART. "Alpha v beta 1 is a receptor for virginia and 108	
mH	-1	Contribute to Cell Annual Contribute to Cell Science, 1995, 1227-38, vol. 108.  JOHN F. MARSHALL, DEBORAH C. RUTHERFORD, ALISON C.E. MCCARTNEY, FRANCESC MITJANS, SINCH V. JOHN F. MARSHALL, DEBORAH C. RUTHERFORD, ALISON C.E. MCCARTNEY, FRANCESC MITJANS, SINCH V. JOHN F. MARSHALL, DEBORAH C. RUTHERFORD, ALISON C.E. MCCARTNEY, FRANCESC MITJANS, SINCH V. JOHN F. MARSHALL, DEBORAH C. RUTHERFORD, ALISON C.E. MCCARTNEY, FRANCESC MITJANS, SINCH V. JOHN F. MARSHALL, DEBORAH C. RUTHERFORD, ALISON C.E. MCCARTNEY, FRANCESC MITJANS, SINCH V. JOHN F. MARSHALL, DEBORAH C. RUTHERFORD, ALISON C.E. MCCARTNEY, FRANCESC MITJANS, SINCH V. JOHN F. MARSHALL, DEBORAH C. RUTHERFORD, ALISON C.E. MCCARTNEY, FRANCESC MITJANS, SINCH V. L. GOLDON, SINCH V. L. GOLDON, AND ALISON C.E. MCCARTNEY, FRANCESC MITJANS, SINCH V. L. GOLDON, SINCH V. L. G. MCCARTNEY, FRANCESC MITJANS, S	: 1
1 44/ /,	- 1	mediate spreading Strangery AND ROBERT C. SPIRO, Biosynthetic Fibringen, and von Willebrand Factor, 5.	.
1		DAVID A. CHENEST Human Melanoma Cell Attachment to Vitronecuii, I was a series of the Control of	-+
mi	ナー	GOODMAN AND informactin," J. of Cell Science, 1995, 122750, vol.  Geodiate spreading on fibronectin," J. of Cell Science, 1995, 122750, vol.  DAVID A. CHERESH AND ROBERT C. SPIRO, "Biosynthetic and Functional Properties of an Arg-Caly-Asp-tilled."  Receptor involved in Human Melanoma Cell Attachment to Vitronectin, Fibrinogen, and von Willebrand Factor," J. of Receptor involved in Human Melanoma Cell Attachment to Vitronectin, Fibrinogen, and von Willebrand Factor," J. of Biological Chemistry, Dec. 25 1987, 17703-11, vol. 262. no. 38.  Biological Chemistry, Dec. 25 1987, 17703-11, vol. 262. no. 38.  HANS KEMPERMAN, YVONNE M. WUNANDS, AND ED ROOS, "Alpha v Integrins on HT-29 Colon Carcinoma Cells HANS KEMPERMAN, YVONNE M. WUNANDS, AND ED ROOS, "Alpha v Integrins on HT-29 Colon Carcinoma Cells HANS KEMPERMAN, YVONNE M. WUNANDS, AND ED ROOS, "Alpha v Integrins on HT-29 Colon Carcinoma Cells HANS KEMPERMAN, YVONNE M. WUNANDS, AND ED ROOS, "Alpha v Integrins on HT-29 Colon Carcinoma Cells HANS KEMPERMAN, YVONNE M. WUNANDS, AND ED ROOS, "Alpha v Integrins on HT-29 Colon Carcinoma Cells HANS KEMPERMAN, YVONNE M. WUNANDS, AND ED ROOS, "Alpha v Integrins on HT-29 Colon Carcinoma Cells HANS KEMPERMAN, YVONNE M. WUNANDS, AND ED ROOS, "Alpha v Integrins on HT-29 Colon Carcinoma Cells HANS KEMPERMAN, YVONNE M. WUNANDS, AND ED ROOS, "Alpha v Integrins on HT-29 Colon Carcinoma Cells HANS KEMPERMAN, YVONNE M. WUNANDS, AND ED ROOS, "Alpha v Integrins on HT-29 Colon Carcinoma Cells HANS KEMPERMAN, YVONNE M. WUNANDS, AND ED ROOS, "Alpha v Integrins on HT-29 Colon Carcinoma Cells HANS KEMPERMAN, YVONNE M. WUNANDS, AND ED ROOS, "Alpha v Integrins on HT-29 Colon Carcinoma Cells HANS KEMPERMAN, YVONNE M. WUNANDS AND ED ROOS, "Alpha v Integrins on HT-29 Colon Carcinoma Cells HANS KEMPERMAN, YVONNE M. WUNANDS AND ED ROOS, "Alpha v Integrins on HT-29 Colon Carcinoma Cells HANS KEMPERMAN, YVONNE M. WUNANDS AND ED ROOS, "Alpha v Integrins on HT-29 Colon Carcinoma Cells HANS KEMPERMAN, YVONNE M. WUNANDS AND ED ROOS, "Alpha v Integrins on H	: 1
1, 6,	1	Receptor involved inv	'
l		HANS KEMPEHMAN, I Mediated Solely by Small Amounts of appra	<del></del>
MH	-	Adhesion to Fibrorisa Cell Research, 1997, 156-64, vol. 234.	-1-
11,410	- 1	Adhesion to Fibronectin is Mediated Solely by Small Amounts of apply of apply the Adhesion to Fibronectin is Mediated Solely by Small Amounts of apply the Adhesion to Fibronecting and Adhesi	<u>"</u> "_
1	731	MAXIME LEHMANUES PICHON AND JACQUES MARVALDI, A standard slota v beta 3, alpha v beta 5, and april	<b>*</b> F
		Call Line 204-HPD0011265 UIG HINDS	
u		and Vitronectin of a Colon Carcinoma Cerr Characteristics of the Carci	
H	1	bela 5:, demost necessary	
<b> </b>			
<b> </b>			
<b> </b>			
<b> </b>			
0			
	_		

•							126		
Sheet 1 of 1							<u>ين</u>		
FORM PTO 1449 (m		TOT COMMERCIA	·	ATTY DOCKET NO. 2002_1351	SERIAL I 19/270	10. P JUL 3223 B 2223 B	1 2 2004		
PAT	ENT AN	MENT OF COMMERCI TRADEMARK OFFICE CES CITED BY APPLICAN	•	APPLICANT Yukio TOYODA et al.	DEM'VEN C				
	(Use seve	ral sheets if necessary) ed to PTO: July 12, 200		FILING DATE October 15, 2002		GROUP 1641			
				S. PATENT DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	FILING DATE IF APPROPRIATE			
	AA								
	АВ								
	AC								
	AD								
	AE				<u> </u>				
	AF								
	AG								
	АН								
	Al								
			FOR	EIGN PATENT DOCUMENTS		т т			
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO		
mH	AJ	0 260 829	3/1988	EP					
M+1.	AK	0 834 557	4/1998	EP					
	AL								
	АМ								
	AN								
		OTHER	R DOCUMENT(S)	(Including Author, Title, Date, Pert	inent Pages, Etc.)		<del></del>		
mtt	AO	J. Orihara, "Sensitiz of Stomatological S	J. Orihara, "Sensitizing Capacity, Cross-Reactivity and Antigenic Determinants of Bisphenol A", The Journal of Stomatological Society, Vol. 59, No. 2, June 1992, pp. 439-455. English Abstract only						
mtt	AP	M. Castillo et al., "A Analytical Chemistr	nalysis of Indu y, Vol. 16, No.	ustrial Effluents to Determi 10, November 12, 1997, p	ne Endocrine-Dis op. 574- 583.	rupting Chemic	cals", Trends in		
mH	AQ	J. Gascon et al., "D (ELISA): Application	etection of En	docrine-Disrupting Pesticion Trends in Analytical Chemical	des by Enzyme-L histry, Vol. 16, No	inked Immunos 5. 10, 1997, pp.	sorbent Assay 554-562.		
EXAMINER 1	lah	n Hadda	8	DATE CONSIDE	RED 1/27/	106			



## SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Application Number	10/720,323
Filing Date	NOVEMBER 24,
<del>-</del>	2003
First Named Inventor	JILL GILES-KOMAR
Group Art Unit	1644
Examiner Name	
Attorney Docket Number	CEN249CIPNP

Examiner Initials No.1 Name of Patentee or Applicant of Cited Document Number (it known) Pages, Columns, Lines, where relevant passages or relevant figures appear

**FOREIGN PATENT DOCUMENTS** Foreign Patent Document Pages, Columns, Lines, where relevant passages or relevant figures Name of Patentee or Examiner Cite Applicant of Cited Document Number<sup>4</sup> Office<sup>3</sup> KindCode<sup>5</sup> appear Initials No.1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), Examiner title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), No.1 volume-issue number(s), publisher, city and/or country where published Initials\* MITJANS et al, "In Vivo Therapy of Malignant Melanoma by Means of Antagonists of ov Integrins," Int. J. Cancer, 2000, pp 716-723, Vol. 87, Wiley-Liss, Inc., Spain.

MITJANS et al, "An anti-ov-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice," Journal of Cell Science, 1995, pp 2825-2838, Vol. 108, The Company of WIL MA Biologists Limited, Great Britain. CASEL et al, "RGD Peptides and Moncolonal Antibodies, Antagonists of q, Integrin, Enter the Cells by Independent Endocytic Pathways," Laboratory Investigation, 2001, pp 1615-1626, Vol. 81, No. 12, The United States and Canadian Academy of Pathology, Inc., USA. MH

Examiner Signature	Makert	laddao	Date Considered	1	127/	06	